意大利多中心队列:甲状腺结节细胞学样本的分子检测
该研究评估Myriapod NGS DNA panel在甲状腺细针穿刺细胞学样本中的性能,对74个TIR3A至TIR5结节进行回顾性分析并与术后病理对照。结果显示在样本DNA合格时灵敏度100%、特异度95.5%,阴性预测值100%,有助于术前风险评估和避免不必要手术。
要点
- 残余液基细胞学材料在89.2%的结节中可提取足量DNA用于分子检测。
- TIR3A结节均为良性,TIR3B中50%为恶性且突变仅见于恶性结节。
- 样本合格时分子检测阴性预测值达100%,有望减少不必要手术。
核心结论
- Myriapod NGS panel有助于甲状腺结节术前评估,高阴性预测值可帮助避免不必要手术。
- 特定突变检出与恶性高度相关,可指导手术规划。
研究设计与样本
- 回顾性分析74个甲状腺结节的细针穿刺细胞学样本,按意大利细胞学分类分为TIR3A、TIR3B、TIR4和TIR5。
- 从残余液基细胞学材料提取DNA,使用Myriapod NGS panel检测16个甲状腺癌相关基因。
- 所有患者均接受手术,进行组织病理学对照。
主要发现
- 残余液基细胞学材料在89.2%的结节中产出足量DNA用于分子检测。
- 所有TIR3A结节组织学均为良性,TIR3B结节中50%为恶性,突变仅见于恶性结节。
- TIR4类别中BRAF V600E是恶性结节中最常见的突变。
- 两个TIR5结节均为甲状腺乳头状癌且携带BRAF V600E突变。
关键数值与推荐
- 样本合格时分子检测灵敏度100%、特异度95.5%、阳性预测值91.7%、阴性预测值100%。
- 纳入不合格样本的意向诊断分析:灵敏度84.6%、特异度87.5%、阳性预测值91.7%、阴性预测值84%。
临床怎么用
- 对细胞学不确定的甲状腺结节,可利用残余液基细胞学材料进行Myriapod NGS panel检测以辅助术前风险评估。
- 分子检测阴性且样本合格时,高阴性预测值可支持避免不必要的手术。
- 检出特定突变(如BRAF V600E)与恶性高度相关,可 informing 手术规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular testing is increasingly used to improve preoperative risk assessment of thyroid nodules, especially those with indeterminate cytology. This study evaluated the performance of the Myriapod next-generation sequencing (NGS) DNA-only cancer panel in fine-needle aspiration cytology thyroid samples, correlating findings with postsurgical diagnoses. METHODS: A retrospective analysis was performed on fine-needle aspiration cytology specimens from 74 thyroid nodules in the TIR3A, TIR3B, TIR4, and TIR5 categories according to the Italian Consensus for the Classification and Reporting of Thyroid Cytology. DNA from these samples, obtained from residual liquid-based cytology material, was analyzed with the Myriapod NGS panel, targeting 16 genes implicated in thyroid cancer. All patients underwent surgery, allowing for histopathologic correlation. RESULTS: The residual liquid-based cytology material yielded adequate DNA for molecular testing in 89.2% of the nodules. All TIR3A (low-risk intermediate) nodules were histologically benign, whereas 50% of TIR3B (high-risk intermediate) nodules were malignant; mutations were identified only in the malignant nodules. In the TIR4 category (suspicious for malignancy), BRAF V600E was the most frequent mutation in malignant nodules. Both TIR5 (malignant) nodules were papillary thyroid carcinomas with a BRAF V600E mutation. The molecular test demonstrated 100% sensitivity, 95.5% specificity, 91.7% positive predictive value, and 100% negative predictive value for samples that were adequate for molecular testing. An intention-to-diagnose analysis that included samples inadequate for molecular testing was also performed, yielding 84.6% sensitivity, 87.5% specificity, 91.7% positive predictive value, and 84% negative predictive value. CONCLUSIONS: The Myriapod NGS panel aids in the preoperative assessment of thyroid nodules. Its high negative predictive value may help avoid unnecessary surgery, whereas the detection of specific mutations strongly correlates with malignancy, thus informing surgical planning.
引用
- Fiorentino V, Giordano W, Pizzimenti C, et al. Molecular profiling of thyroid nodules on cytologic samples: Findings from an Italian multi-institutional cohort. Cancer Cytopathol. 2026. PMID: 41370117. doi:10.1002/cncy.70065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。